RxDoctor Payments Data

William Feltner, DO

Internal Medicine · Campbellsville, KYNPI 1497861777

Payments from drug & device makers

$1,347in general payments, 2019–2025

Across 64 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$493
  • Amgen$418
  • Novo Nordisk$215
  • AbbVie$121
  • Lilly USA, LLC$41
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$33
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$1,347100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,347 in reported general payments places this provider in the 70th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$77,607
Medicare patients
177
Services billed
1,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$66,904
JanuviaSitagliptin Phosphate48$48,940
EliquisApixaban45$38,960
OzempicSemaglutide28$33,517
FarxigaDapagliflozin Propanediol20$14,887
Levemir FlexpenInsulin Detemir13$5,140
Tresiba Flextouch U-100Insulin Degludec14$4,720
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,289
Levothyroxine Sodium392$2,828
Losartan Potassium450$2,634
Pravastatin Sodium232$2,016
Ziprasidone Hcl24$1,768
Atorvastatin Calcium342$1,729
Potassium Chloride158$1,703
Rosuvastatin Calcium135$1,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$66,90451 claims
MerckJanuvia$11$48,94048 claims
Novo NordiskOzempic$215$33,51728 claims
AstraZenecaFarxiga$493$14,88720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Campbellsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →